Terbium-161 treatment for prostate cancer that has spread
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new radioactive treatment, terbium-161, for men with advanced prostate cancer that has stopped responding to other treatments. It aims to see if this treatment can target and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have advanced prostate cancer that has spread and is progressing despite prior treatments like chemotherapy and hormone therapy.
- You have had a PSMA PET scan showing strong cancer activity.
- You are in generally good health, with adequate organ function and an expected survival of at least 6 months.
- You have not had prior treatment with radioactive isotopes (except for diagnostic scans).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.